This study will evaluate the efficacy and safety of various treatment and retreatment regimens of MabThera. All patients will receive concomitant methotrexate, 10-25mg once weekly either orally or parenterally. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00422383?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
